Medtronic FY27 growth and dividend boost

Medtronic's FY26 results drove this narrative, with the medical device giant posting its strongest annual revenue growth in a decade, totaling $36.4bn, up 8.4% YoY. Q4 results also topped expectations, with revenue of $9.8bn. Medtronic expects FY27 growth in the 6.75% to 7.25% range, and boosted its dividend.

This narrative impacts the medical devices sector, with Medtronic's robust performance indicating strong demand for its products. The company's growth outlook and dividend hike may attract investors seeking stable, dividend-paying healthcare stocks, potentially driving further sector gains.

Investors should watch Medtronic's FY27 earnings release, scheduled for August 25, 2027, to confirm its growth trajectory. Additionally, any updates on the company's pipeline and regulatory approvals for new products will shape this narrative, as these could drive further growth or setbacks.